Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of November 17, 2026, GILD trades at $169.53 with a market cap of $207.86B and a P/E ratio of -55.34. GILD moved +1.59% today. Year to date, GILD is +43.91%; over the trailing twelve months it is +37.19%. Its 52-week range spans $93.37 to $176.58. Analyst consensus is strong buy with an average price target of $173.76. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for GILD, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $169.53 |
| Market Cap | $207.86B |
| P/E Ratio | -55.34 |
| EPS | $-2.60 |
| Dividend Yield | 0.82% |
| 52-Week High | $176.58 |
| 52-Week Low | $93.37 |
| Volume | 4.43M |
| Avg Volume | 0 |
| Revenue (TTM) | $30.46B |
| Net Income | $-3.24B |
| Gross Margin | 79.59% |
23 analysts cover GILD: 0 strong buy, 18 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $173.76.